The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Getting a quote of 56p to sell on ii, but not giving me an e-quote to buy ("Market Best" on as little as 5000 shares).. Good signs
We'll know the answer in about a month. At the moment no reason to suspect not..
With the sudden jump to 59p on the ask, and 54p on the bid, wondering whether we have another (or the same) buyer back?
ignore last post - the RNS last year was discussing 5th product launched - current one discusses 8th product approved..
Interestingly this is their "8th" product approved by the FDA. Last RNS I recall was for their 5th (30th July 19). Unless I missed it they have had 2 further product launches in the past year, that don't appear to have been RNS'd?
Good to see the rise on the DSE today (119Tk - £1.09 equivalent). May be helped by the Oxford vaccine restarting trials in India..
Still 62p to buy on a dummy test. MMs just dropping the sell/bid, but not sure their game - maybe accumulating (to fill an order), maybe just trying to stimulate the market? SP movement is on very low volume and not sure how well a tree shake will work on this share..
With the P3 AZ/Oxford vaccine study resumed in the UK (and assume soon in India?), + India looking like they are going to do positive U turn on granting Emergency Use Authorisation (EUA) to a Covid vaccine (although we can't say for certain this is the Oxford one) - you'd hope the SP would start ticking up... Quite a few dots to join though and still unknowns e.g. if India does grant EUA to a vaccine will it be the Oxford one (although that has to be a front runner) and will Bangladesh follow the lead and grant the same in Bangladesh? - in which case BXP could be selling vaccine as early as Q1 next year - all speculation - but that's the nature of investing I guess.
I'm sure it's been discussed already but in order to obtain a CMA - SNG would have to agree, and put in place, their proposed study to meet the MA conditions, before being granted the MA. Who knows but may in part explain the updates to their ongoing study and means we could see authorisation on the data to-date? Not sure why the M Fools wouldn't at least give some consideration to this route to market? - again sorry if it's all been discussed to death?
Links below may also be on interest
https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/conditional-marketing-authorisation
https://www.abpi.org.uk/media/1357/onestopshop_adaptive_licensing.pdf
p.s. the authorities will most likely want to review the COPD data as part of the submission (supporting evidence of effect and safety). They don't want surprises from other soon to finish studies,with the same product.
just tried a couple of dummy buys on ii - not giving an electronic quote at present (just "market best") - can sell ok...
And the DSE is closed today, so the news hasn't been factored into the SP on the DSE (well technically it shouldn't have)
Hi Libero - I believe that was the order we were talking about the other day, that needed to be filled. The order would have been put in at 55p (a few days ago) and the MMs were filling it by buying at 53.7p, but not selling so easily to PIs. Just for interest I did a couple of dummy sells/buys this morning and i don't believe the buyer has finished.
I wouldn't be surprised (if we see enough sells) to see another buy of around 100k shares @c56p declared in a few days, if/when that particular order has been filled. All IMO of course... and again based on my understanding of how these things work
https://www.thedailystar.net/business/news/pharma-stocks-flying-amid-pandemic-1949921
So if we're only looking at a 20% reduction in profit, in the final quarter (although not sure if they mean relative to expectation, Q3 or relative to last years final quarter) we'd be looking at a final EPS of around 8 - 8.25Tk. No surprises they believe this will bounce back in Q1.
Hi Cyberduck - Just to add to- "looking back to April 2017 when BXP @ 69.5p. BXPHARMA @ 120 in their own currency. Now at 113.7 in their own currency."
Since April 2017 the NAV has increased 30% (60Tk to 78Tk) and the EPS by 55% (4.03 for the 1st 3Q's of 2017 to 6.48 for the current 1st 3Qs)..
Hoping we start moving towards the shares true value..
Hi Libero - I think you've just pushed the ask up :) (ok only by 0.5p - but all helps)
On a dummy sell I could offload 100k shares quite easily, and quoted an electronic price of 52p through ii (52.5p for 5k shares). I couldn't even buy 1k of shares electronically - only gave me market best (which probably would have ended up at 58p maybe). My thoughts are there's a larger order to fill (or kill) and thus the MMs are working this at present. We'll see in a day or 2 maybe , as they can delay reporting it until it's filled. Again I'm no expert in the way these MMs work - but makes sense to me at least. A "tree shake" is probably not going to work, to obtain our shares, as PIs know from the DSE there's nothing fundamentally up with the company.
Hi Cyberduck - I'm not fully up to speed with all the MM tricks but those quotes, I guess, could suggest they want to fill a large order i.e. don't want to sell to PI's but keen to obtain shares for as little as they can?
A close of 102p equivalent on the DSE (114 tk), on very high volume. I'm not sure if the movement we've seen today on the LSE simply reflects the large increases we're seeing on the DSE, or whether we have a GDR buyer in the background, that MMs are attempting to fill?
The current spread looks a little off putting, but should close. The volume seems to fluctuate, on the LSE, and more often linked to news. The announcement of the dividend will be around late Oct. Expecting this to be around 2p per share (if they give 30% of profit), so a yield just under 4% on today's SP, and hopefully a little movement . Still a way to go to reach the highs of a few years ago - but fingers crossed. We never reach SP parity with the DSE, but the trends have run in the same direction, in the past at least. Reading the link I posted earlier, you can see that the Directors may have to buy a few more shares to reach their 30% requirement. I assume this has to be on the DSE though? Shame they can't get their quota up buying the half price AIM listed GDRs - which provide a better dividend yield (given the lower SP)..
https://thefinancialexpress.com.bd/stock/ten-issues-grab-24pc-transaction-1597464471
Courtesy of mfhmfh on the ADFVN board
https://asia.nikkei.com/Business/Pharmaceuticals/Bangladesh-s-Beximco-thrives-on-coronavirus-challenges